Minerva Neurosciences

Minerva Neurosciences EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Minerva Neurosciences (NERV) as of Nov 5, 2026 is -290.32 M USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 6.00 M USD — a change of -4,937.80% (lower).

EBITDA

-290.32 MUSD

YoY

-4,937.80%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Minerva Neurosciences is 2025 -290.32 M USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Minerva Neurosciences was 2024 6.00 M USD. It decreases by -4,937.80% lower compared to the previous year.

The Minerva Neurosciences EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
-51.73 M USD
Jan 1, 2019
-75.87 M USD
Jan 1, 2020
1.85 M USD
Jan 1, 2021
-45.38 M USD
Jan 1, 2022
-24.70 M USD
Jan 1, 2023
-21.99 M USD
Jan 1, 2024
6.00 M USD
Jan 1, 2025
-290.32 M USD
The Minerva Neurosciences EBITDA history
YEAREBITDAYoY
-290.32 MUSD-4,937.80%
6.00 MUSD-127.29%
-21.99 MUSD-10.99%
-24.70 MUSD-45.57%
-45.38 MUSD-2,557.10%
1.85 MUSD-102.43%
-75.87 MUSD+46.66%
-51.73 MUSD+25.65%
-41.17 MUSD+37.16%
-30.02 MUSD+14.96%
-26.11 MUSD-52.41%
-54.87 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Minerva Neurosciences Stock analysis

What does Minerva Neurosciences do? Minerva Neurosciences Inc, based in Waltham, US, is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system diseases. The company, listed in 2014, operates with a portfolio including MIN-101 for schizophrenia, MIN-202 for insomnia and depression, MIN-117 for depression, and MIN-301 for Parkinson's disease. It employs seven full-time staff and targets neurological conditions through innovative biotechnology approaches. Minerva Neurosciences is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Minerva Neurosciences stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Minerva Neurosciences is -290.32 M USD in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Minerva Neurosciences changed from 6.00 M USD to -290.32 M USD, representing a -4,937.80% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Minerva Neurosciences since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Minerva Neurosciences historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Minerva Neurosciences

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Minerva Neurosciences